Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Arkansas › Springdale
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Springdale, AR keessatti
Qorannoo 15 Kansara Qara'a Non-Small Cell f Springdale fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- Highlands Oncology Group - Springdale /ID# 277132, Springdale
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Highlands Oncology Group, PA, Springdale
- Highlands Oncology Group, Springdale
- Highlands Oncology Group, PA, Rogers · Miili 10 fagaatti
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Namoota walitti qabaa jiraSadarkaa 3
- Highlands Oncology Group-Research Department ( Site 0062), Springdale
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Highlands Oncology Group, Springdale
- Highlands Oncology Group, Rogers · Miili 10 fagaatti
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- Highlands Oncology Group, PA, Springdale
- Highlands Oncology Group, PA, Rogers · Miili 10 fagaatti
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Highlands Oncology Group, Springdale
Pan-tumor MRD Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Highlands Oncology Group (HOG), Springdale
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Springdale
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Namoota walitti qabaa jiraSadarkaa 3
- Local Institution - 0686, Springdale
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Springdale
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Namoota walitti qabaa jiraSadarkaa 2/3
- Highlands Oncology Group - Springdale, Springdale
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Highlands Oncology Group, Springdale
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Namoota walitti qabaa jiraSadarkaa 3
- Highlands Oncology Group, Springdale
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Highlands Oncology Group, Springdale
- Highlands Oncology Group, Rogers · Miili 10 fagaatti
BostonGene and Exigent Genomic INsight Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Highlands Oncology Group, Rogers · Miili 10 fagaatti
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Springdale keessatti
- SchizophreniaQorannoo 7
- Dhibee QaraQorannoo 6
- Kansara MetastatikiiQorannoo 6
- Kansarii ColorectalQorannoo 5
- Saree OljooQorannoo 5
- Saree (Gosoota Hunda)Qorannoo 5
- Dhibee Gaddii GuddaaQorannoo 5
- Dukkana BladderQorannoo 4
- DepreshiniiQorannoo 4
- Kansaara EsophagusQorannoo 3
- ManiaQorannoo 3
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 3
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.